FIFARMA Joins the Alliance for the Elimination of HIV in the Americas
FIFARMA Joins the Alliance for the Elimination of HIV in the Americas
Estimated reading time: 3 minutes
To reach the goal of eliminating HIV by 2030 in the Americas, FIFARMA signed its membership in the Pan American Health Organization’s (PAHO) Alliance for the Elimination of HIV during the AIDS 2026 Conference in Rio de Janeiro. This step responds to a clear need: Latin America faces the challenge of accelerating the reduction of new cases, which demands collaboration across all sectors.
What Is the Alliance for the Elimination of HIV in the Americas?
It is a regional political and technical platform created by PAHO to coordinate all the actors involved in the HIV response, with the goal of:
- Facilitating the arrival of new prevention, diagnostic, and treatment tools, and expanding their use across countries.
- Promoting greater regulatory harmonization—meaning that approval processes across countries become more aligned and avoid duplicating efforts.
- Driving predictable and sustainable financing mechanisms, so that programs don’t depend on budgets that change from year to year.
The initiative is part of the “Health for All” regional agenda and is aligned with PAHO’s Elimination Initiative, which seeks to eliminate more than 30 communicable diseases in the region by 2030.
A Region Moving at Two Speeds: The Data Behind the Urgency

This is the regional picture according to PAHO and UNAIDS figures (2025):
Latin America
- In 2025, approximately 150,000 new HIV infections were recorded—17% more than in 2010.
- There were 32,000 HIV-related deaths reported, representing a 46% reduction compared to that same year.
These figures show that treatment is working and saving lives. However, prevention still isn’t reducing new infections enough, which have remained largely stalled since 2022.
The Caribbean
Between 2010 and 2024, the Caribbean reduced new infections by 30% and deaths by 65%. This is proof that the trend can be reversed when policies, financing, and collaboration align.
Why Cooperation Is the Missing Piece?

A scientific breakthrough that doesn’t reach people in time fails to fulfill its purpose, and ensuring that timely access depends on joint decisions by multiple actors.
“This membership reflects our commitment to joining forces, promoting innovation, and strengthening collaboration so that the elimination of HIV as a public health threat becomes a reality in the Americas.”
— Yaneth Giha, Executive Director of FIFARMA.
What the Innovative Pharmaceutical Industry Brings to the Table?
The sector’s role in this Alliance is clear: to serve as the bridge between scientific development and people. Through this membership, FIFARMA commits to providing the evidence and data needed to design more agile public policies. The goal is to ensure that the most innovative preventive therapies and treatments are integrated equitably and sustainably into the region’s health systems.
What This Means for Patients in the Region?
For scientific advances to fulfill their purpose, they must be integrated into health systems in a timely, equitable, and sustainable way. That is precisely the central objective of this Alliance: to consolidate a joint effort to close current gaps and promote evidence-based public policies.
Want to explore the evidence and data FIFARMA makes available for informed health decision-making?
Explore our studies and publications at fifarma.org and learn more about PAHO’s Alliance for the Elimination of HIV in the Americas.